Virtus Equity & Convertible Income Fund Announces Distribution and Discloses Sources of Distribution – Section 19(a) Notice
HARTFORD, Conn.–(BUSINESS WIRE)–Virtus Equity & Convertible Income Fund (NYSE: NIE) today announced the following quarterly distribution: Ticker... Read more.
Virtus Stone Harbor Emerging Markets Income Fund Announces Distributions and Provides Update on Reorganization
HARTFORD, Conn.–(BUSINESS WIRE)–Virtus Stone Harbor Emerging Markets Income Fund (NYSE: EDF) today announced the following monthly distributions: Amount... Read more.
Virtus Stone Harbor Emerging Markets Total Income Fund Provides Update on Reorganization and Announces Monthly Distribution
HARTFORD, Conn.–(BUSINESS WIRE)–Virtus Stone Harbor Emerging Markets Total Income Fund (NYSE: EDI) announced today its reorganization with and into Virtus... Read more.
Tiny Reports Third Quarter 2023 Results
VICTORIA, British Columbia–(BUSINESS WIRE)–Tiny Ltd. (formerly, WeCommerce Holdings Ltd.) (“Tiny” or “the “Company”) (TSXV: TINY) (OTCQX: TNYZF),... Read more.
Curacao Offers Hundreds of Thousands of Dollars in Black Friday Discounts Through Its Doorbusters Deals
Curacao – Named Best Shopping Destination by Los Angeles Times’ 2023 Best of the Southland Awards – to Launch Early Season of Savings starting on Thanksgiving... Read more.
Geospace Technologies Reports Profitable Fourth Quarter and Fiscal Year 2023 Results
HOUSTON–(BUSINESS WIRE)–#energyexploration–Geospace Technologies Corporation (NASDAQ: GEOS) (“the “Company”) today announced net income... Read more.
Certain Virtus Closed-End Funds Announce Three Monthly Distributions: NCV, NCZ, CBH
HARTFORD, Conn.–(BUSINESS WIRE)–Virtus Convertible & Income Fund (NYSE: NCV), Virtus Convertible & Income Fund II (NYSE: NCZ), and Virtus Convertible... Read more.
Green Dot Appoints Dave Harden as Chief Technology Officer
Digital Bank and Fintech Announces Executive Updates Aimed at Driving Performance and Efficiency AUSTIN, Texas–(BUSINESS WIRE)–#BaaS–Green Dot... Read more.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy... Read more.
Virtus Artificial Intelligence & Technology Opportunities Fund Announces Distributions and Discloses Sources of Distribution – Section 19(a) Notice
HARTFORD, Conn.–(BUSINESS WIRE)–Virtus Artificial Intelligence & Technology Opportunities Fund (NYSE: AIO) today announced the following monthly... Read more.